Do analysts recommend CCM or BRTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Concord Medical Services 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, CCM or BRTX?

Concord Medical Services has higher revenue and earnings than Biorestorative Therapies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Concord Medical Services $65.85M 0.28 -$13.27M N/A N/A Biorestorative Therapies $357.87K 20.65 -$14.24M -$1.07 N/A

Do analysts rate BRTX or ADVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Advanced Biomed 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to BRTX or ADVB?

In the previous week, Advanced Biomed had 20 more articles in the media than Biorestorative Therapies. MarketBeat recorded 22 mentions for Advanced Biomed and 2 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 0.93 beat Advanced Biomed's score of 0.29 indicating that Biorestorative Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biorestorative Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Advanced Biomed 1 Very Positive mention(s) 2 Positive mention(s) 18 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BRTX or BMGL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, BRTX or BMGL?

Basel Medical Group has higher revenue and earnings than Biorestorative Therapies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biorestorative Therapies $357.87K 20.65 -$14.24M -$1.07 N/A Basel Medical Group $14.55M 0.62 -$9.50M N/A N/A

Do analysts rate BRTX or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to BRTX or MGRX?

In the previous week, Mangoceuticals had 2 more articles in the media than Biorestorative Therapies. MarketBeat recorded 4 mentions for Mangoceuticals and 2 mentions for Biorestorative Therapies. Mangoceuticals' average media sentiment score of 0.95 beat Biorestorative Therapies' score of 0.93 indicating that Mangoceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biorestorative Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mangoceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ACON or BRTX?

Aclarion currently has a consensus price target of $7.50, suggesting a potential upside of 209.92%. Given Aclarion's stronger consensus rating and higher probable upside, equities research analysts clearly believe Aclarion is more favorable than Biorestorative Therapies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to ACON or BRTX?

In the previous week, Aclarion had 1 more articles in the media than Biorestorative Therapies. MarketBeat recorded 3 mentions for Aclarion and 2 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 0.93 beat Aclarion's score of 0.74 indicating that Biorestorative Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclarion 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biorestorative Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Biorestorative Therapies (BRTX) Competitors

$0.29 -0.02 (-7.17%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$0.29 +0.00 (+1.03%)

As of 07/24/2026 07:32 PM Eastern

Compare

BRTX vs. CCM, ADVB, BMGL, MGRX, and ACON

Should you buy Biorestorative Therapies stock or one of its competitors? MarketBeat compares Biorestorative Therapies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biorestorative Therapies include Concord Medical Services (CCM), Advanced Biomed (ADVB), Basel Medical Group (BMGL), Mangoceuticals (MGRX), and Aclarion (ACON). These companies are all part of the "healthcare" industry.

How does Biorestorative Therapies compare to Concord Medical Services?

Concord Medical Services (NYSE:CCM) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

Concord Medical Services has higher revenue and earnings than Biorestorative Therapies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Concord Medical Services	$65.85M	0.28	-$13.27M	N/A	N/A
Biorestorative Therapies	$357.87K	20.65	-$14.24M	-$1.07	N/A

In the previous week, Biorestorative Therapies had 1 more articles in the media than Concord Medical Services. MarketBeat recorded 2 mentions for Biorestorative Therapies and 1 mentions for Concord Medical Services. Concord Medical Services' average media sentiment score of 1.00 beat Biorestorative Therapies' score of 0.93 indicating that Concord Medical Services is being referred to more favorably in the media.

Company	Overall Sentiment
Concord Medical Services	Positive
Biorestorative Therapies	Positive

69.4% of Biorestorative Therapies shares are held by institutional investors. 46.5% of Concord Medical Services shares are held by company insiders. Comparatively, 13.6% of Biorestorative Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Concord Medical Services has a beta of -0.97, meaning that its stock price is 197% less volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

Concord Medical Services has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Concord Medical Services' return on equity of 0.00% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Concord Medical Services	N/A	N/A	N/A
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Concord Medical Services	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Concord Medical Services beats Biorestorative Therapies on 7 of the 11 factors compared between the two stocks.

How does Biorestorative Therapies compare to Advanced Biomed?

Biorestorative Therapies (NASDAQ:BRTX) and Advanced Biomed (NASDAQ:ADVB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

In the previous week, Advanced Biomed had 20 more articles in the media than Biorestorative Therapies. MarketBeat recorded 22 mentions for Advanced Biomed and 2 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 0.93 beat Advanced Biomed's score of 0.29 indicating that Biorestorative Therapies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biorestorative Therapies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Advanced Biomed	1 Very Positive mention(s)	2 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Advanced Biomed has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Advanced Biomed's return on equity of 87.74% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
Advanced Biomed	N/A	87.74%	64.49%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Advanced Biomed	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biorestorative Therapies has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market. Comparatively, Advanced Biomed has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market.

69.4% of Biorestorative Therapies shares are held by institutional investors. 13.6% of Biorestorative Therapies shares are held by insiders. Comparatively, 27.0% of Advanced Biomed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Advanced Biomed has lower revenue, but higher earnings than Biorestorative Therapies. Biorestorative Therapies is trading at a lower price-to-earnings ratio than Advanced Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$357.87K	20.65	-$14.24M	-$1.07	N/A
Advanced Biomed	N/A	N/A	-$3.26M	$4.82	3.94

Summary

Advanced Biomed beats Biorestorative Therapies on 8 of the 12 factors compared between the two stocks.

How does Biorestorative Therapies compare to Basel Medical Group?

Biorestorative Therapies (NASDAQ:BRTX) and Basel Medical Group (NASDAQ:BMGL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

Basel Medical Group has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Basel Medical Group's return on equity of 0.00% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
Basel Medical Group	N/A	N/A	N/A

69.4% of Biorestorative Therapies shares are held by institutional investors. 13.6% of Biorestorative Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Basel Medical Group has higher revenue and earnings than Biorestorative Therapies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$357.87K	20.65	-$14.24M	-$1.07	N/A
Basel Medical Group	$14.55M	0.62	-$9.50M	N/A	N/A

In the previous week, Biorestorative Therapies and Biorestorative Therapies both had 2 articles in the media. Biorestorative Therapies' average media sentiment score of 0.93 beat Basel Medical Group's score of 0.44 indicating that Biorestorative Therapies is being referred to more favorably in the media.

Company	Overall Sentiment
Biorestorative Therapies	Positive
Basel Medical Group	Neutral

Biorestorative Therapies has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.15, suggesting that its share price is 85% less volatile than the broader market.

Summary

Biorestorative Therapies and Basel Medical Group tied by winning 5 of the 10 factors compared between the two stocks.

How does Biorestorative Therapies compare to Mangoceuticals?

Biorestorative Therapies (NASDAQ:BRTX) and Mangoceuticals (NASDAQ:MGRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

Biorestorative Therapies has a net margin of -3,088.27% compared to Mangoceuticals' net margin of -4,639.13%. Mangoceuticals' return on equity of -112.00% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
Mangoceuticals	-4,639.13%	-112.00%	-104.96%

Biorestorative Therapies has higher earnings, but lower revenue than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$357.87K	20.65	-$14.24M	-$1.07	N/A
Mangoceuticals	$414.58K	21.56	-$20.64M	-$1.49	N/A

Biorestorative Therapies has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.28, suggesting that its share price is 128% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Mangoceuticals had 2 more articles in the media than Biorestorative Therapies. MarketBeat recorded 4 mentions for Mangoceuticals and 2 mentions for Biorestorative Therapies. Mangoceuticals' average media sentiment score of 0.95 beat Biorestorative Therapies' score of 0.93 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biorestorative Therapies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mangoceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

69.4% of Biorestorative Therapies shares are held by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are held by institutional investors. 13.6% of Biorestorative Therapies shares are held by company insiders. Comparatively, 16.0% of Mangoceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Mangoceuticals beats Biorestorative Therapies on 8 of the 13 factors compared between the two stocks.

How does Biorestorative Therapies compare to Aclarion?

Aclarion (NASDAQ:ACON) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

Aclarion has higher earnings, but lower revenue than Biorestorative Therapies. Biorestorative Therapies is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$77.88K	76.50	-$7.23M	-$9.03	N/A
Biorestorative Therapies	$357.87K	20.65	-$14.24M	-$1.07	N/A

Aclarion currently has a consensus price target of $7.50, suggesting a potential upside of 209.92%. Given Aclarion's stronger consensus rating and higher probable upside, equities research analysts clearly believe Aclarion is more favorable than Biorestorative Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biorestorative Therapies has a net margin of -3,088.27% compared to Aclarion's net margin of -10,320.51%. Aclarion's return on equity of -54.41% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,320.51%	-54.41%	-51.71%
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

7.5% of Aclarion shares are owned by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are owned by institutional investors. 0.0% of Aclarion shares are owned by company insiders. Comparatively, 13.6% of Biorestorative Therapies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Aclarion has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

In the previous week, Aclarion had 1 more articles in the media than Biorestorative Therapies. MarketBeat recorded 3 mentions for Aclarion and 2 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 0.93 beat Aclarion's score of 0.74 indicating that Biorestorative Therapies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclarion	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biorestorative Therapies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aclarion beats Biorestorative Therapies on 10 of the 16 factors compared between the two stocks.

Get Biorestorative Therapies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BRTX vs. The Competition

Export

Metric	Biorestorative Therapies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.96M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-0.27	21.29	27.11	23.64
Price / Sales	20.65	160.31	512.89	89.27
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	7.25	7.88	10.28	6.07
Net Income	-$14.24M	$23.86M	$3.60B	$331.99M
7 Day Performance	-13.20%	-3.82%	-1.27%	-0.63%
1 Month Performance	-26.40%	-2.61%	-0.37%	-2.00%
1 Year Performance	-82.10%	32.79%	18.30%	13.62%

Biorestorative Therapies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BRTX Biorestorative Therapies	1.1452 of 5 stars	$0.29 -7.2%	N/A	-82.4%	$7.96M	$357.87K	N/A	7
CCM Concord Medical Services	1.3058 of 5 stars	$4.30 +6.7%	N/A	-21.6%	$17.50M	$65.85M	N/A	970	Positive News Short Interest Decrease Gap Down High Trading Volume
ADVB Advanced Biomed	1.4736 of 5 stars	$12.25 +73.0%	N/A	N/A	$11.70M	N/A	1.41	40	Analyst Upgrade Gap Up High Trading Volume
BMGL Basel Medical Group	0.3513 of 5 stars	$5.88 -1.0%	N/A	-78.5%	$9.30M	$8.90M	N/A	36	Short Interest Increase Gap Down
MGRX Mangoceuticals	1.1561 of 5 stars	$0.51 +8.5%	N/A	-70.2%	$8.09M	$460K	N/A	3	News Coverage Analyst Upgrade Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BRTX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biorestorative Therapies (BRTX) Competitors

BRTX vs. CCM, ADVB, BMGL, MGRX, and ACON

How does Biorestorative Therapies compare to Concord Medical Services?

Summary

How does Biorestorative Therapies compare to Advanced Biomed?

Summary

How does Biorestorative Therapies compare to Basel Medical Group?

Summary

How does Biorestorative Therapies compare to Mangoceuticals?

Summary

How does Biorestorative Therapies compare to Aclarion?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRTX vs. The Competition

Biorestorative Therapies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biorestorative Therapies (BRTX) Competitors

BRTX vs. CCM, ADVB, BMGL, MGRX, and ACON

How does Biorestorative Therapies compare to Concord Medical Services?

Which has stronger valuation and earnings, CCM or BRTX?

Does the media favor CCM or BRTX?

Do insiders & institutionals believe in CCM or BRTX?

Which has more volatility and risk, CCM or BRTX?

Is CCM or BRTX more profitable?

Do analysts recommend CCM or BRTX?

Summary

How does Biorestorative Therapies compare to Advanced Biomed?

Does the media refer more to BRTX or ADVB?

Is BRTX or ADVB more profitable?

Do analysts rate BRTX or ADVB?

Which has more risk & volatility, BRTX or ADVB?

Do insiders & institutionals hold more shares of BRTX or ADVB?

Which has preferable valuation and earnings, BRTX or ADVB?

Summary

How does Biorestorative Therapies compare to Basel Medical Group?

Is BRTX or BMGL more profitable?

Do institutionals and insiders believe in BRTX or BMGL?

Do analysts rate BRTX or BMGL?

Which has stronger valuation & earnings, BRTX or BMGL?

Does the media refer more to BRTX or BMGL?

Which has more volatility & risk, BRTX or BMGL?

Summary

How does Biorestorative Therapies compare to Mangoceuticals?

Is BRTX or MGRX more profitable?

Which has stronger valuation & earnings, BRTX or MGRX?

Which has more volatility & risk, BRTX or MGRX?

Do analysts rate BRTX or MGRX?

Does the media refer more to BRTX or MGRX?

Do institutionals and insiders believe in BRTX or MGRX?

Summary

How does Biorestorative Therapies compare to Aclarion?

Which has better valuation & earnings, ACON or BRTX?

Do analysts recommend ACON or BRTX?

Is ACON or BRTX more profitable?

Do institutionals and insiders have more ownership in ACON or BRTX?

Which has more volatility & risk, ACON or BRTX?

Does the media refer more to ACON or BRTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRTX vs. The Competition

Biorestorative Therapies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools